Applications of Antisense Therapies to Restenosis
LeRoy E. Rabbani
Springer Science & Business Media, Feb 28, 1999 - Medical - 184 pages
Restenosis, the proliferation of smooth muscle cells (SMC) that line blood vessels, often follows angioplasty. Despite advances in cardiology, restenosis continues to affect up to 40% of the over 500,000 patients who undergo angioplasty each year.
Applications of Antisense Therapies to Restenosis is the first volume to address the potential of using antisense therapies to inhibit the restenosis that occurs after percutaneous transluminal angioplasty and coronary stenting. The work critically examines the application of various antisense therapies for inhibiting restenosis.
What people are saying - Write a review
We haven't found any reviews in the usual places.
RESTENOSIS THE CLINICAL PROBLEM
THE PATHOBIOLOGY OF RESTENOSIS A PARADIGM FROM CLINICAL AND EXPERIMENTAL STUDIES
CORONARY REPAIR AND RESTENOSIS CELLULAR BASIS FOR ANTISENSE APPROACHES
VASCULAR SMOOTH MUSCLE CELL BIOLOGY AND RESTENOSIS
VASCULAR ANTISENSE THERAPY DIRECTED AGAINST cmyc cmyb and PCNA
PHOSPHOROTHIOATE OLIGODEOXYNUCLEOTIDES AS INHIBITORS OF GENE EXPRESSION ANTISENSE AND NONANTISENSE EFFECTS
MOLECULAR THERAPIES FOR VASCULAR DISEASE ALTERING THE BALANCE BETWEEN CELL GROWTH AND CELL DEATH
Other editions - View all
adhesion adventitial angiographic antisense agents antisense oligonucleotides aortic arterial injury AS-c-myb ODN atherectomy atherosclerosis balloon angioplasty balloon injury basic fibroblast growth bFGF binding Biol Chem c-myb c-myc cell cycle cell proliferation cellular Circulation Clin Invest clinical Coll Cardiol coronary artery culture delivery demonstrated drug endothelial cells extracellular matrix fibroblast growth factor G-quartet gene expression guanosine heparin human induced inhibition inhibitory effects interleukin-4 intimal kinase lesion mechanism mediated mitogens modulation molecules mRNA muscle cell migration muscle cell proliferation myofibroblasts neointimal formation neointimal hyperplasia nitric oxide Nucleic Acids oligomers PCNA PDGF percutaneous transluminal coronary phenotype phosphorothioate oligonucleotides plasminogen activator platelet platelet-derived growth factor porcine protein proteoglycans PTCA rat carotid artery receptor regulation remodeling restenosis restenosis after percutaneous restenosis rates Schwartz smooth muscle cells specific stent structures studies synthesis target mRNA therapy thrombosis tissue transforming growth factor-p transluminal coronary angioplasty uptake vascular injury vascular smooth muscle vessel wall vitro vivo VSMC